Expert Review of Pharmacoeconomics & Outcomes Research

Article	Citations
How to create value with constrained budgets in oncological care? A narrative review	48
Direct medical and indirect absenteeism costs among working adult ADHD patients in the United States	46
The value of cycleways to improve population physical activity levels: a systematic review of economic evaluations	39
The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology	38
Cost per responder analysis of lebrikizumab versus tralokinumab in moderate to severe atopic dermatitis from a United States perspective	35
Indication-based pricing of the pharmaceuticals in Croatia: case-study	23
Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment	23
Engagement of medication users in the development and implementation of digital medication adherence technologies: a multi-stakeholder study	19
Cost-effectiveness of mechanical thrombectomy versus intravenous thrombolysis in acute ischemic stroke: a systematic review	17
Social care data in the UK; current landscape, challenges, and future recommendations	17
Clinical and economic impact analysis of viscosupplementation with hylan G-F 20 versus hyaluronic acids and no viscosupplementation for the treatment of knee osteoarthritis in Colombia	15
Adherence to augmentation therapy for the treatment of major depressive disorder	15
Consumption of antidepressants and economic austerity in Brazil	14
A methodological guide for implementing and interpreting results of probabilistic analysis	12
Time from approval to reimbursement recommendations in healthcare systems with centralized HTA processes. Focus on the Polish HTA agency	12
Direct diabetes-related healthcare expenditures in Slovenia: recent evolution and future projections based on population-level data	12
The impact of under-investment on health in Southern and Central Eastern European Countries	12
The role of insurance policies in the drug pricing landscape	12
Cost-effectiveness analysis of nivolumab-chemotherapy as first-line therapy for locally advanced/metastatic gastric cancer: a United States payer perspective	12
A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain	12
Cost-effectiveness analysis of tofacitinib for the treatment of moderate to severe rheumatoid arthritis: a systematic review and meta-analysis	11
Medication adherence research: expert perspectives on key HEOR trends for 2026	11
Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2− advanced breast cancer	11
The impact of bone turnover marker on medication adherence and the health economics-related consequences	10
Mapping of the health of the Nation Outcomes Scale (HoNOS) and Positive and Negative Symptom Scale (PANSS) to the EQ-5D-3L in psychosis patients using the PHAMOUS study	10

Cost effectiveness of non-pharmacological interventions for fatigue in patients with long-term conditions: a systematic literature review	10
International comparability of reference unit costs of education services: when harmonizing methodology is not enough (PECUNIA project)	10
Cost consequence minimization and budget impact model for introducing the fully liquid combined acellular hexavalent vaccine into the Dominican Republic’s expanded immunization plan	9
The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States	9
Valuing quality of life for economic evaluations in cancer: navigating multiple methods	9
Regulatory perspectives on post-market evidence generation schemes for high-risk medical devices: a systematic review	9
Pembrolizumab combined with chemotherapy versus placebo combined with chemotherapy for HER2-negative advanced gastric cancer in China: a cost-effectiveness analysis	9
Cost-utility analysis of multiple sclerosis rehabilitation in Iran	9
Systematic reviews of machine learning in healthcare: a literature review	9
Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer in the Chinese healthcare system	9
Health and economic impact of 20-valent pneumococcal conjugate vaccine for adults aged 66–84 years in Japan and Shiga prefecture	9
Access to medicines, care, and services for multiple sclerosis patients in Central and Eastern European countries: a comparative analysis	9
Digital measures in epilepsy in low-resourced environments	8
Patients’ health related quality of life after massive weight loss reconstruction in the Netherlands	8
Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis	8
Evaluation instruments for executive functions in children and adolescents: an update of a systematic review	8
Cost–utility analysis of dupilumab compared with endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyps. Evaluation in Colombia, a developing country	8
Individual vs societal perspectives: implications on quantitative benefit-risk assessment of vaccination	8
Adherence to oral anticoagulants in patients with non-valvular atrial fibrillation: the role of patients’ characteristics and out-of-pocket payments	8
Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation	8
Burden of illness among intermittent catheter users with non-neurogenic urinary retention in Denmark	7
Value elements and methods of value-based pricing for drugs in Japan: a systematic review	7
The pharmaceutical market: a transdisciplinary description of concepts and their implications	7
Real-world analysis of the economic and therapeutic burden in advanced breast cancer patients in Italy	7
Valuing prevention: lessons and recommendations from a Dutch expert committee	7
Developing the Lebanese health economic evaluation guideline	7
Impact of patient’s financial burden of COVID-19 treatment on antiviral prescription rates and clinical and economic outcomes	7
The socioeconomic burden of cervical cancer and its implications for strategies required to achieve the WHO elimination targets	7
How relevant is the BMI for cost-of-illness studies in the 21st century?	7
Knowledge, perception and application of pharmacoeconomics among healthcare professionals in Malaysia	7
Are quality-adjusted life years (QALYs) becoming more expensive? Evidence from economic evaluations of diabetic therapeutics	7
Physician and patient adherence in hypertension trials: a point of view on an important issue to resolve	7
Economic evaluation of an add-on module to reduce intrusive suicidal mental images in patients with depressive symptoms	7
Cost of rimegepant and lasmiditan associated adverse events, for acute treatment in migraine in Spain	7
Systematic review on the use of cost-benefit analysis to evaluate food environment interventions	7
Intravenous and subcutaneous vedolizumab for moderately to severely active ulcerative colitis in Iran: a model-based cost-effectiveness evaluation	7
Qualitative research on the acceptance of evolving evidence for HTA body approval of innovative health technologies in selected European countries	7
Burden of disease of chronic pain in Ecuador	6
Transdisciplinary health economics for 2050: the challenge of preventing the adverse health effects of obesity, inequalities, and climate change	6
Economic analysis of cerliponase alfa for treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2)	6
Development and implementation of a stratified enhanced recovery after surgery pathway for ventral hernia repair	6
Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma	6
Management of low back pain in the Brazilian public health system: budget impact analysis of the implementation of Pilates exercises compared to usual care	6
Bridging the gap: enhancing medication adherence through research and innovation	6
Economic and humanistic burden of chronic liver diseases in the United States	6
Mapping the World Health Organization Disability Assessment Scale 2.0 to the EQ-5D-5L in patients with mental disorders	6
A retrospective observational analysis of the real-world care pathway of people with hereditary transthyretin amyloidosis with polyneuropathy in Italy	6
Timely access to new drugs in a single-payer system: policy analysis from South Korea’s reimbursement framework	6
Reimagining pharmacoeconomics in the age of artificial intelligence: opportunities, challenges, and future directions	6
Incorporating diagnostic testing into economic evaluations of tumour-agnostic therapies	6

Precision medicine in Thoracic Oncology: understanding disparities to tackle inequities in access	6
The potential public health impact of new immunization strategies for the prevention of RSV in children in Panama	6
Methodological standards for comparative effectiveness research: considerations for evidentiary review for medicare drug price negotiation	5
Budget impact analysis of transurethral water vapor therapy for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in the Spanish national healthcare system	5
Clinical and economic outcomes associated with intravenous albumin fluid use in the intensive care unit: a retrospective cohort study	5
Workplace productivity losses due to cancer: findings from an Australian longitudinal population survey (2009–2021)	5
The hidden burden of atopic dermatitis in central and Eastern European countries	5
Psychometric properties of outcome measures for freezing of gait in Parkinson’s disease: a systematic review and meta-analysis	5
How do patients value features of biological medicine in rheumatoid arthritis? A discrete choice experiment	5
A cost analysis of a simplified model for HCV screening and treatment at a tertiary hospital in Zimbabwe	5
Economic benefits of global Collaborative Health technology	5
Using natural language processing to analyze unstructured patient-reported outcomes data derived from electronic health records for cancer populations: a systematic review	5
Work absenteeism, disability, and lost wages among patients with acute myeloid leukemia and their caregivers: a cohort study using US administrative claims and productivity data	5
Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening	5
Tenecteplase in managing acute ischemic stroke: a long-term cost–utility analysis in Iran	5
Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain	5
Adherence to asthma and COPD inhaled therapies in low- and middle-income countries: a narrative review	5
A comprehensive measurement of hemophilia economic burden in Iraq: a field-based study	5
Preferences of people with diabetes for diabetes care in Germany: a discrete choice experiment	5
The economic impact of pharmacist intervention during pandemics	4
Digital decision aids and prenatal outcomes: a systematic review and meta-analysis	4
Cost-effectiveness analysis of cenobamate for epilepsy patients with drug-resistant focal onset seizures in the Netherlands	4
Secondary healthcare resource utilization and related costs associated with influenza-related hospital admissions in adult patients, England 2016 – 2020	4
Implementing a Managed Entry Agreement Framework in Cyprus	4
Evaluating reporting of patient-reported outcomes in peptic ulcer disease: a meta-epidemiological study of randomized controlled trials	4
Economic burden of cervical cancer and premalignant lesions associated with human papilloma virus: a societal perspective	4
Capturing the holistic value of biosimilars in Europe – part 1: a historical perspective	4
Correction	4
Trastuzumab deruxtecan versus chemotherapy treated in patients with HER2-positive metastatic breast cancer: a cost-effectiveness analysis based on the DESTINY-Breast02 trial	4
Cost-effectiveness of toripalimab plus chemotherapy versus chemotherapy as first-line treatment for advanced non-small cell lung cancer in China: a societal perspective	4
Value-based health care in Western countries: a scoping review on the implementation of patient-reported-outcomes sets for hospital-based interventions	4
The economics of prevention and quality of care: policy insights from the EU’s COVID-19 response	4
Enhancing pharmacist intervention targeting based on patient clustering with unsupervised machine learning	4
The impact of comprehensive public hospital reform on economic burden of inpatients with chronic obstructive pulmonary disease: evidence from a pilot city in western China	4
The value of functional genomics: a contingent valuation	4
Public value judgments about the criteria for reimbursement of medicines in South Korea	4
Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program	4
Inebilizumab for neuromyelitis optica spectrum disorders in Italy: a budget impact model	4
Perceptions of risk sharing agreements in South Korea from the viewpoints of key stakeholders: a convergent parallel mixed approach	4
Value assessment of new interventions for Alzheimer’s disease dementia in Japan based on literature review and group interview	4
Costs for global guideline-based diagnosis of mucormycosis in patients with neutropenia, hematopoietic stem cell, or solid organ transplantation – a perspective of the German healthcare system	4
Use of machine learning to predict bladder cancer survival outcomes: a systematic literature review	4
Cost-effectiveness of HIV prevention interventions in sub-Saharan Africa (2019–2025): a systematic review	4
Pharmaceutical innovativeness index: methodological approach for assessing the value of medicines – a case study of oncology drugs	4
The Lebanese health economic evaluation guideline	4
A roadmap for applying machine learning when working with privacy-sensitive data: predicting non-response to treatment for eating disorders	4
Perspectives in prospective comparative economic evaluations: a systematic review	4
The short-term impact of copayment reductions for government subsidised medicines in Australia	4
Negating the burden of hip fracture in high-risk populations: a narrative review of epidemiology, costs, and multifaceted mitigation strategies	4
Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in Greece	4
Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China	4
The health production model and the crucial role of health promotion	3
Cost-effectiveness of MRI strategies for early prostate cancer detection: a systematic review	3
Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece	3
Barriers to digital endpoints in data collection in low and middle-income countries	3
Systematic review of the impact of health care expenditure on health outcome measures: implications for cost-effectiveness thresholds	3
Economic evaluation of toripalimab plus chemotherapy compared with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma in China	3
A review of caregiver costs included in cost-of-illness studies	3
Climate-related risk and pharmaceutical market dynamics in India and USA: evidence from transfer entropy, BEKK GARCH, and coherence wavelet	3
Pharmacovigilance and outcomes: experience from Saudi Arabia narrative review	3
Cost-effectiveness of first-line sintilimab plus chemotherapy versus chemotherapy for advanced esophageal carcinoma in China	3
How do hospital characteristics and ties relate to the uptake of second-generation biosimilars? A longitudinal analysis of Portuguese NHS hospitals, 2015–2021	3
Real-world healthcare costs and resource utilization in patients with von Willebrand disease and angiodysplasia	3
Can artificial intelligence separate the wheat from the chaff in systematic reviews of health economic articles?	3
Budget impact and cost per responder analysis of upadacitinib for the treatment of moderate to severe atopic dermatitis from the perspective of the social security and the private sector in Argentina	3
Design and testing of a health economic Markov model for treatment of anorexia nervosa	3
Assessing the impact of kidney cancer-related premature mortality and productivity loss in Greece and Portugal	3
System dynamics simulation for evaluating implementation strategies of genomic sequencing: tutorial and conceptual model	3
Budget impact of low-dose computed tomography screening for lung cancer in Argentina	3
The implications of cardiac device cybersecurity responsibilities and challenges faced by policymakers, manufacturers, and patients	3
Consumption and expenditure of drugs used for the treatment of hypercholesterolemia: a governance analysis	3
The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention	3
Economics perspectives on understanding antimicrobial use and resistance: a scoping review from theory to practice	3
Normative data and socio-demographic determinants of the dermatology life quality index in a large online sample of the Hungarian population	3
The impact of fibrodysplasia ossificans progressiva (FOP) on patients and their family members: results from an international burden of illness survey	3
Economic burden of suicides and suicide attempts in low- and middle-income countries: a systematic review of costing studies	3
Comparative efficacy of later-line therapies for metastatic colorectal cancer: a network meta-analysis of survival curves	3
How can patients shape digital medicine? A rapid review of patient and public involvement and engagement in the development of digital health technologies for neurological conditions	3
Cost-utility analysis of Lenvatinib vs. Sorafenib in unresectable hepatocellular carcinoma in Iran	3
Trends in antidepressant utilization, expenditure, and demographic prescribing patterns in Jordan: a retrospective analysis	3

What are the costs of managing neck and low back pain in Brazil? Investigation of a ten-year period from the perspective of the Brazilian public health system	3
Burden of disease of chronic pain in Colombia	3
Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma	3
Financial evaluation of value-creating biosimilar development candidates: a business case study of low-, medium- and high-sales biosimilars	3
Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China	3
What to expect in 2024: important health economics and outcomes research (HEOR) trends	3
Alternative approaches to measuring value: an update on innovative methods in the context of the United States Medicare drug price negotiation program	3
The utility and impact of digital endpoints for improving breast cancer outcomes	3
Patient-relevance of outcome measures in breast cancer clinical trials: a cross-sectional comparative analysis of patient preferences and trials conducted between 2014 and 2024	3
Cost-effectiveness analysis of point-of-care A1C tests in the primary care setting of Iran	3
Willingness to pay for a quality-adjusted life year (QALY) in Pakistan: implications for health policy	3
Exploring the approach to parameter uncertainty in early economic evaluations of surgical technology – a systematic review	3
The impact of non-pharmacological interventions on adherence to medication and persistence in dyslipidaemia and hypertension: a systematic review	3
Cost of care and budget impact of novel first-line treatments in patients with locally advanced or metastatic urothelial carcinoma from the Colombian healthcare system perspective	3
Cost-effectiveness analysis of atezolizumab plus bevacizumab and chemotherapy for the treatment of metastatic, persistent, or recurrent cervical cancer (BEATcc)	2
Oxygen saturation thresholds for bronchiolitis at high altitudes: a cost-effectiveness analysis	2
Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Sing	2
Quality-adjusted life years for HER2-positive, early-stage breast cancer using trastuzumab-containing regimens in the context of cost-effectiveness studies: a systematic review	2
Proposed method for economic evaluation based on basket trials: a case study of pembrolizumab	2
A systematic review of health state utility values in Thai cancer patients	2
Advancing the economics of prevention: emerging methods and approaches	2
Value based healthcare and Health Technology Assessment for emerging market countries: joint efforts to overcome barriers	2
Cost-effectiveness of durvalumab with or without olaparib as a first-line treatment for dMMR type of advanced/recurrent endometrial cancer	2
Survival analysis of famotidine administration routes in non-traumatic intracerebral hemorrhage patients: based on the MIMIC-IV database	2
Impact of early-stage immunotherapy on health and work productivity in the Czech Republic, 2024–2033	2
Analysis of prescriptive monitoring regarding the current therapeutic landscape of rheumatoid arthritis: the experience of an Italian local health authority	2
Cost-effectiveness of atezolizumab plus bevacizumab as first-line therapy for metastatic renal cell carcinoma	2
Meta-analysis of traditional Chinese medicine on chronic kidney disease	2
Leveraging sensor-based functional outcomes to enhance understanding of the patient experience: challenges and opportunities	2
Concerns on methodological assumptions in the health economic evaluation of return-to-work interventions	2
Emerging trends: the involvement of community pharmacists in the planning and execution of pharmaceutical policies and economics	2
How should we measure the use of social care and informal care?	2
Challenges with integrating early-stage cancer trial endpoints into economic models: review of health technology recommendations for adjuvant or neoadjuvant therapies in Canada	2
Economic evaluation of clinical pharmacy service using integrated health system in tertiary care hospital	2
Impact of adherence on the cost-effectiveness of apixaban and rivaroxaban in stroke prevention among patients with atrial fibrillation in the United States	2
Gene therapies, uncertainty, and decision-making: thinking about the last mile at the first step	2
Bringing the patient’s perspectives forward in drug development and health-care evaluation	2
Payer and Developer perspectives on alternative payment models	2
Understanding the upper bound of survival for conducting and critically appraising economic evaluations of low-risk cancers	2
Correction	2
Time to treat the climate and nature crisis as one indivisible global health emergency	2
Budget impact analysis of daratumumab for light-chain amyloidosis in Cyprus	2
An early economic analysis of medical cannabis for the treatment of chronic pain	2
Conceptualization of a decision-analytic model in youth mental health: an application of stakeholder engagement in model development in the Netherlands	2
Cost-effectiveness of second- or third-line treatment with tisotumab vedotin for metastatic or recurrent cervical cancer	2
Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial	2
Estimated value of productivity lost due to childhood chickenpox in the United Kingdom: a survey of parents	2
Feasibility assessment of using the MiToS staging system for conducting economic evaluation in amyotrophic lateral sclerosis	2
A retrospective budget impact analysis of fidaxomicin treatment for Clostridioides difficile infections (CDI) in Germany	2
Unleashing economic potential of AI-driven technology to prevent adverse events and sub-optimal treatment	2
Real-world analysis of cost, treatment patterns, and outcomes of patients with metastatic cutaneous squamous cell carcinoma in the US	2
The cost-utility analysis of adding ocrelizumab to the treatment plan for primary progressive multiple sclerosis in Iran	2
Direct healthcare costs for people with cerebral palsy in the Brazilian unified health system between 2015 and 2019	2
The cost-of-illness of multiple sclerosis in Jordan	2
Cost–utility analysis of latanoprost unidose cationic emulsion preservative-free versus latanoprost unidose in the treatment of open-angle glaucoma and ocular hypertension patients in Spain	2
Cost-utility analysis of duloxetine in osteoarthritis: from Chinese healthcare perspective	2
Diabetes disparities in diabetes health care access and outcomes during the COVID-19 pandemic in the United States	2
Switching hemophilia A patients to an extended half-life agent on a prophylactic basis: an economic appraisal	2
Cost-effectiveness analysis of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer	2
Cost-effectiveness analysis of FOLFOXIRI plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment of metastatic colorectal cancer	2
Evaluating high-cost technologies – no need to throw the baby out with the bathwater	2
Time and personnel costs associated with adverse event (AE) management among patients with chronic lymphocytic leukemia (CLL)	2
Prevention, artificial intelligence, and mathematics in health economics: a framework for dynamic value modeling under long-term uncertainty	2
A scoping review on patient heterogeneity in economic evaluations of precision medicine based on basket trials	2
Economic and healthcare resource utilization for hereditary transthyretin amyloidosis with polyneuropathy in Spain: real-world insights from early-stage patients and mutation carriers	2
Estimate of the cost per responder for treatment with biological therapies of moderate-to-severe plaque psoriasis in Colombia for first-year and maintenance periods	2
How unprofessional behaviours between healthcare staff threaten patient care and safety	2
Effect of immuno-oncology on clinical and economic outcomes for a selection of cancers in Italy	2
Challenges in resource allocation of diagnostic tests in Spain	2
Risk prediction algorithms in guiding antiviral therapy initiation among patients with chronic hepatitis B in Thailand: an economic evaluation and budget impact analysis	2
Clinical and economic outcomes of patients with cardiorenal and metabolic diseases: a real-world analysis in a single Italian Local Health Unit	2
Cost-effectiveness of cholecystectomy compared to conservative management in people presenting with uncomplicated symptomatic gallstones or cholecystitis in India	2
Comprehensive economic value evaluation of adding tislelizumab to first-line chemotherapy for patients with extensive-stage small cell lung cancer in China	2
Preference of young adults for COVID-19 vaccination in the United Kingdom: a discrete choice experiment	2
Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab, and benralizumab added to the standard of care in adults with severe asthma in Colombia	2
Is the shift in treatment patterns towards new, more expensive drugs still driving the increase in pharmaceutical expenditure? A decomposition analysis of expenditure data in Sweden 1990–2022	2
An exploratory cost-effectiveness analysis of a novel tissue valve compared with mechanical valves for surgical aortic valve replacement in subgroups of people aged 55–64 and 65+ with aortic stenosis	2
First-Line Tislelizumab for Advanced or Metastatic Esophageal Squamous Cell Carcinoma:A Cost-Effectiveness Analysis	2
Multicenter, cross-sectional study of the economic burden of multiple sclerosis and cost-driving factors	2
Cost-effectiveness of Arg16Gly in ADRB2 pharmacogenomic-guided treatment for pediatric asthma	2
The economic benefits of fracture prevention	2
Adapting Health Technology Assessment agency standards for surrogate outcomes in early stage cancer trials: what needs to happen?	2